| Literature DB >> 23008757 |
Bong Gun Song1, Ju Hyeon Oh, Yong Hwan Park, Gu Hyun Kang, Woo Jung Chun.
Abstract
Background. Tako-tsubo cardiomyopathy (TTC) is typically triggered by an acute emotional or physical stress events. Aim of this study was to investigate the impact of emotional stressors on clinical features, laboratory parameters, electrocardiographic and echocardiographic findings in patients with TTC. Methods. Of 103 patients enrolled from the TTC registry database, fifteen patients had emotional triggers (E group), and 88 patients had physical triggers or no triggers (other group). Results. Most clinical presentations and in-hospital courses were similar between the groups. However, E group had higher prevalence of chest pain (87 versus 42 %, P = 0.001), palpitation (27 versus 6%, P = 0.008), whereas other group had higher prevalence of cardiogenic shock (35 versus 7%, P = 0.027). E group had significantly higher corrected QT intervals (median, 477.5 versus 438 ms, P = 0.001), and left ventricular ejection fraction (LVEF) (mean, 45.7 versus 39.6%, P = 0.001), but lower hs-CRP (median, 0.1 versus 3.3 mg/L, P = 0.001), CK-MB (median, 5.5 versus 11.9 ng/mL, P = 0.047), troponin-I (median, 1.0 versus 3.2 ng/mL, P = 0.011), and NT-proBNP levels (median, 2145 versus 4939 pg/mL, P = 0.020). Other group required more frequent hemodynamic support and had significantly longer intensive care unit (median, 3 versus 1 days, P = 0.005) and in-hospital (median, 17 versus 3 days, P = 0.001) durations. Conclusion. The clinical features of TTC are different between groups with and without preceding emotional stressors. The TTC group with preceding emotional stressors was more likely to have preserved cardiovascular reserve and lesser likely to require hemodynamic support than other group although the entire prognosis of TTC is excellent regardless of triggering stressors.Entities:
Year: 2012 PMID: 23008757 PMCID: PMC3447323 DOI: 10.1155/2012/843876
Source DB: PubMed Journal: Cardiovasc Psychiatry Neurol ISSN: 2090-0171
Figure 1Preceding stressful events of 103 patients with TTC. Emotional stressors were documented in 15% of patients, whereas physical stressors were documented in 67% of patients and 18% of patients had no triggering stressor.
The comparison of clinical characteristics between the subgroups.
| Total ( | E group ( | Other group ( |
| |
|---|---|---|---|---|
| Age (years)† | 59.0 (52.0–72.0) | 58.0 (54.0–78.0) | 59.0 (52.0–72.0) | 0.578 |
| Male gender, | 33 (32) | 2 (13) | 31 (35) | 0.093 |
| Body surface area (m2) | 1.6 ± 0.2 | 1.5 ± 0.1 | 1.6 ± 0.2 | 0.093 |
| Hypertension, | 32 (31) | 2 (13) | 30 (34) | 0.108 |
| Diabetes mellitus, | 22 (21) | 2 (13) | 20 (23) | 0.412 |
| Current smoker, | 8 (8) | 2 (13) | 6 (7) | 0.384 |
| Underlying diseases | ||||
| Stroke/transient ischemic attack, | 6 (6) | 0 (0) | 6 (7) | 0.297 |
| Liver cirrhosis, | 2 (2) | 0 (0) | 2 (2) | 0.555 |
| Chronic renal failure, | 7 (7) | 0 (0) | 7 (8) | 0.258 |
| Malignancy, | 18 (17) | 0 (0) | 18 (20) | 0.054 |
| Clinical presentation | ||||
| Chest pain, | 50 (49) | 13 (87) | 37 (42) | 0.001* |
| Dyspnea, | 54 (52) | 9 (60) | 45 (51) | 0.525 |
| Palpitation, | 9 (9) | 4 (27) | 5 (6) | 0.008* |
| Loss of consciousness, | 1 (1) | 0 (0) | 1 (1) | 0.678 |
| Nausea/vomiting, | 10 (10) | 0 (0) | 10 (11) | 0.169 |
| Cardiogenic shock, | 32 (31) | 1 (7) | 31 (35) | 0.027* |
| Pulmonary edema, | 42 (41) | 6 (40) | 36 (41) | 0.947 |
†Presented as median (interquartile range). *Significant finding.
The comparison of electrocardiographic changes, laboratory, and angiographic findings between the subgroups.
| Total ( | E group ( | Other group ( |
| |
|---|---|---|---|---|
| Electrocardiographic changes | ||||
| Life-threatening arrhythmia, | 16 (16) | 0 (0) | 16 (18) | 0.072 |
| Heart rate (beats/min)† | 80.0 (66.0–91.0) | 66.0 (58.0–72.0) | 84.0 (71.0–95.0) | 0.001* |
| Atrial fibrillation, | 6 (6) | 0 (0) | 6 (7) | 0.297 |
| Corrected QT interval (ms)† | 438.0 (422.8–486.0) | 477.5 (434.0–544.0) | 438.0 (417.0–482.3) | 0.002* |
| ST-segment elevation, | 73 (71) | 13 (87) | 60 (68) | 0.145 |
| Q-wave, | 13 (13) | 0 (0) | 13 (15) | 0.111 |
| T-wave inversion, | 79 (77) | 12 (80) | 67 (76) | 0.744 |
| Laboratory findings | ||||
| hs-CRP (mg/L)† | 2.3 (0.8–11.1) | 0.1 (0.1–10.0) | 3.3 (1.0–11.4) | 0.001* |
| NT-proBNP (pg/mL)† | 3210.0 (1102.0–30181.0) | 2145.0 (613.3–5059.0) | 4939.0 (1458.0–33017.0) | 0.020* |
| Cardiac enzymes | ||||
| Peak CK (ng/mL)† | 279.0 (93.0–632.0) | 279.0 (519.0–619.5) | 270.5 (90.0–607.0) | 0.421 |
| Peak CK-MB (ng/mL)† | 11.9 (2.8–33.9) | 5.5 (1.5–23.7) | 11.9 (3.8–34.8) | 0.047* |
| Peak troponin-I (ng/mL)† | 2.0 (0.2–11.1) | 1.0 (0.1–3.3) | 3.2 (0.2–13.3) | 0.011* |
| Angiographic findings | ||||
| LVEDP (mmHg)† | 19.0 (13.0–25.0) | 14.0 (9.0–20.0) | 19.0 (13.0–25.0) | 0.039* |
Life-threatening arrhythmia: third-degree atrioventricular block, ventricular tachycardia, ventricular fibrillation, cardiac arrest; LVEDP: left ventricular end diastolic pressure.
†Presented as median (inter-quartile range). *Significant finding.
The comparison of echocardiographic findings between the subgroups.
| Total ( | E group ( | Other group ( |
| |
|---|---|---|---|---|
|
| ||||
| Ballooning pattern | ||||
| Typical TTC pattern, | 79 (77) | 11 (73) | 68 (77) | 0.554 |
| Inverted TTC pattern, | 20 (19) | 4 (27) | 16 (18) | |
| Mid-ventricular pattern, | 4 (4) | 0 (0) | 4 (5) | |
| Localized pattern, | 0 (0) | 0 (0) | 0 (0) | |
| LVEF (%) | 40.5 ± 8.0 | 45.7 ± 4.3 | 39.6 ± 8.2 | 0.001* |
| LVEDD (mm) | 51.8 ± 6.1 | 49.5 ± 2.7 | 52.2 ± 6.9 | 0.009* |
| LVESD (mm) | 36.9 ± 7.0 | 30.8 ± 4.8 | 37.9 ± 6.8 | 0.001* |
| LAVI (mL/m2) | 28.2 ± 14.7 | 22.0 ± 3.8 | 29.3 ± 15.6 | 0.077 |
| RVSP (mmHg) | 33.7 ± 3.6 | 33.4 ± 3.2 | 33.8 ± 3.7 | 0.696 |
| E/E′ | 10.8 ± 5.5 | 10.1 ± 2.9 | 11.0 ± 5.8 | 0.638 |
| SAM | 13 (13) | 3 (20) | 10 (11) | 0.352 |
| Significant MR, | 25 (24) | 5 (33) | 20 (23) | 0.376 |
| Significant AR, | 6 (6) | 2 (13) | 4 (5) | 0.179 |
| Significant TR, | 15 (15) | 4 (27) | 11 (13) | 0.151 |
|
| ||||
| LVEF (%) | 62.9 ± 4.7 | 65.4 ± 5.1 | 62.5 ± 4.5 | 0.061 |
| LVEDD (mm) | 49.7 ± 5.3 | 50.4 ± 5.0 | 49.6 ± 5.4 | 0.664 |
| LVESD (mm) | 31.2 ± 4.2 | 29.6 ± 4.8 | 31.0 ± 4.1 | 0.187 |
| LAVI (mL/m2) | 27.6 ± 14.2 | 25.8 ± 3.4 | 27.7 ± 15.2 | 0.684 |
| RVSP (mmHg) | 31.8 ± 4.7 | 31.7 ± 4.7 | 32.0 ± 4.0 | 0.280 |
| E/E′ | 10.5 ± 5.3 | 11.7 ± 3.1 | 9.5 ± 3.3 | 0.478 |
| SAM | 0 (0) | 0 (0) | 0 (0) | — |
| Significant MR, | 9 (9) | 2 (13) | 7 (8) | 0.495 |
| Reversible MR, | 16 (16) | 3 (20) | 13 (15) | 0.605 |
| Significant AR, | 4 (4) | 0 (0) | 4 (5) | 0.400 |
| Significant TR, | 9 (8) | 1 (7) | 8 (9) | 0.224 |
TTE: transthoracic echocardiography; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter; LAVI: left atrial volume index; RVSP: right ventricular systolic pressure; E/E′: early diastolic mitral inflow velocity/early diastolic annular velocity; SAM: systolic anterior motion of anterior mitral leaflet; MR: mitral regurgitation; TRL: tricuspid regurgitation; AR: aortic regurgitation.
*Significant finding.
The comparison of clinical courses and management between the subgroups.
| Total ( | E group ( | Other group ( |
| |
|---|---|---|---|---|
| Use of inotropics, | 28 (27) | 2 (13) | 26 (30) | 0.192 |
| Use of IABP, | 12 (12) | 0 (0) | 12 (14) | 0.128 |
| Use of ACEI or ARB, | 57 (55) | 10 (67) | 47 (53) | 0.340 |
| Use of beta blocker, | 21 (20) | 4 (27) | 17 (19) | 0.514 |
| Use of diuretic, | 40 (39) | 2 (13) | 38 (43) | 0.028* |
| Temporal pacemaker, | 10 (10) | 0 (0) | 10 (11) | 0.169 |
| Cardioversion, | 6 (6) | 0 (0) | 6 (7) | 0.297 |
| ICU hospitalization, | 63 (61) | 5 (33) | 58 (66) | 0.017* |
| ICU hospitalization (days)† | 2.0 (0–5.0) | 1.0 (0–2.0) | 3.0 (0–6.5) | 0.005* |
| Hospitalization (days)† | 14.0 (7.0–28.0) | 3.0 (3.0–9.0) | 17.0 (8.0–32.0) | 0.001* |
| In-hospital cardiac mortality, | 0 (0) | 0 (0) | 0 (0) | — |
| Cardiac mortality during followup, | 0 (0) | 0 (0) | 0 (0) | — |
| Mortality during followup, | 14 (14) | 0 (0) | 14 (16) | 0.097 |
| Recurrence, | 0 (0) | 0 (0) | 0 (0) | — |
IABP: intra-aortic balloon pump; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; ICU: intensive care unit.
†Presented as median (inter-quartile range).
*Significant finding.